DE602004002275D1 - Verfahren zur herstellung rekombinanterpolyklonaler proteine - Google Patents

Verfahren zur herstellung rekombinanterpolyklonaler proteine

Info

Publication number
DE602004002275D1
DE602004002275D1 DE602004002275T DE602004002275T DE602004002275D1 DE 602004002275 D1 DE602004002275 D1 DE 602004002275D1 DE 602004002275 T DE602004002275 T DE 602004002275T DE 602004002275 T DE602004002275 T DE 602004002275T DE 602004002275 D1 DE602004002275 D1 DE 602004002275D1
Authority
DE
Germany
Prior art keywords
cells
collection
library
nucleic acid
recombinant polyclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004002275T
Other languages
English (en)
Other versions
DE602004002275T2 (de
Inventor
S Haurum
C Wiberg
W Coljee
Jacqueline Sharon
Chiou-Ying Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of DE602004002275D1 publication Critical patent/DE602004002275D1/de
Application granted granted Critical
Publication of DE602004002275T2 publication Critical patent/DE602004002275T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
DE602004002275T 2003-01-07 2004-01-07 Verfahren zur herstellung rekombinanterpolyklonaler proteine Expired - Lifetime DE602004002275T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43840303P 2003-01-07 2003-01-07
DKPA200300008 2003-01-07
US438403P 2003-01-07
DK200300008 2003-01-07
US47601803P 2003-06-05 2003-06-05
US476018P 2003-06-05
PCT/DK2004/000001 WO2004061104A2 (en) 2003-01-07 2004-01-07 Method for manufacturing recombinant polyclonal proteins

Publications (2)

Publication Number Publication Date
DE602004002275D1 true DE602004002275D1 (de) 2006-10-19
DE602004002275T2 DE602004002275T2 (de) 2007-09-06

Family

ID=32718469

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004002275T Expired - Lifetime DE602004002275T2 (de) 2003-01-07 2004-01-07 Verfahren zur herstellung rekombinanterpolyklonaler proteine

Country Status (19)

Country Link
US (1) US9163232B2 (de)
EP (2) EP1762617A1 (de)
JP (2) JP4589914B2 (de)
KR (1) KR101024443B1 (de)
AT (1) ATE338816T1 (de)
AU (1) AU2004203727C1 (de)
BR (1) BRPI0406678A (de)
CA (1) CA2512647C (de)
DE (1) DE602004002275T2 (de)
DK (1) DK1583830T3 (de)
EA (1) EA013225B1 (de)
ES (1) ES2273202T3 (de)
HK (1) HK1078896A1 (de)
IL (1) IL169101A (de)
MX (1) MXPA05006724A (de)
NZ (1) NZ541458A (de)
PT (1) PT1583830E (de)
SI (1) SI1583830T1 (de)
WO (1) WO2004061104A2 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1771483A1 (de) 2004-07-20 2007-04-11 Symphogen A/S Rekombinanter polyklonaler anti-rhesus-d-antikörper und herstellungsverfahren
ATE548657T1 (de) * 2004-07-20 2012-03-15 Symphogen As Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie
EP1907561B1 (de) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Zellinien zur expression eines bei der herstellung amidierter produkte geeigneten enzyms
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
ES2369946T3 (es) 2007-03-01 2011-12-09 Symphogen A/S Procedimiento para clonación de anticuerpos análogos.
DK2132229T3 (en) 2007-03-01 2016-06-20 Symphogen As Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
CA2678628A1 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
HUE032301T2 (en) 2007-08-30 2017-09-28 Daiichi Sankyo Co Ltd Anti-EPHA2 antibody
EP2725035A1 (de) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
SI2206727T1 (sl) 2007-10-11 2015-06-30 Daiichi Sankyo Company, Limited Protitelo, ki cilja osteoklast - soroden protein Siglec-15
CA2722348A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
KR20110058861A (ko) * 2008-08-29 2011-06-01 심포젠 에이/에스 조류 유래 항체의 클로닝 방법
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
US8575316B2 (en) 2009-04-09 2013-11-05 Daiichi Sankyo Company, Limited Anti-Siglec-15 antibody
KR20120098664A (ko) 2009-10-15 2012-09-05 아바시아 바이오로직스, 인크. 소화 기관에서 국소 활성을 가진 항체 치료법
KR101814852B1 (ko) 2010-10-29 2018-01-04 다이이찌 산쿄 가부시키가이샤 신규 항 dr5 항체
EP2635604B1 (de) 2010-11-01 2016-11-30 Symphogen A/S Pan-her-antikörperzusammensetzung
WO2012068317A2 (en) 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
DK2703486T3 (en) 2011-04-25 2018-05-28 Daiichi Sankyo Co Ltd ANTI-B7-H3 ANTIBODY
SG10201601882PA (en) 2011-12-22 2016-04-28 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2832855A4 (de) 2012-03-30 2016-02-24 Daiichi Sankyo Co Ltd Neuartiger anti-siglec-15-antikörper
ES2660472T3 (es) 2012-03-30 2018-03-22 Daiichi Sankyo Company, Limited Anticuerpo anti-Siglec-15 modificado con CDR
JP6188681B2 (ja) 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
AU2013254313B2 (en) 2012-04-27 2017-03-30 Daiichi Sankyo Company, Limited Anti-ROBO4-antibody
AU2013255537B2 (en) 2012-05-02 2018-02-15 Symphogen A/S Humanized pan-her antibody compositions
JP2015163047A (ja) * 2012-06-20 2015-09-10 国立大学法人 東京大学 タンパク質の迅速改良法
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP3470431A1 (de) 2012-09-27 2019-04-17 Merus N.V. Bispezifische igg-antikörper als t-zell-engager
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
MX2016003643A (es) 2013-09-30 2016-12-20 Daiichi Sankyo Co Ltd Anticuerpo anti-lps o11.
TWI664977B (zh) 2013-10-08 2019-07-11 第一三共股份有限公司 抗ｆｇｆｒ２抗體及其與其他藥劑之組合
WO2015093925A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Isaac Método de producción de anticuerpos específicos
WO2015130172A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3
US11279770B2 (en) 2014-02-28 2022-03-22 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
CN107847601A (zh) 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
DK3115376T3 (en) 2015-07-10 2018-11-26 Merus Nv HUMANT CD3 BINDING ANTIBODY
WO2017053889A2 (en) 2015-09-23 2017-03-30 Precision Immunotherapy, Inc. Flt3 directed car cells for immunotherapy
TWI836305B (zh) 2015-09-24 2024-03-21 日商第一三共股份有限公司 抗ｇａｒｐ抗體及其製造方法及用途
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
US11618785B2 (en) 2016-12-22 2023-04-04 Daiichi Sankyo Company, Limited Anti-CD3 antibody and molecules comprising the antibody
AU2018218753A1 (en) 2017-02-07 2019-09-26 Daiichi Sankyo Company, Limited Anti-GPRC5D antibody and molecule containing same
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
PE20191741A1 (es) 2017-04-05 2019-12-12 Symphogen As Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
JP7181535B2 (ja) 2017-06-30 2022-12-01 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
SG11202000759XA (en) 2017-07-27 2020-02-27 Daiichi Sankyo Co Ltd Anti-cd147 antibody
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
TW201927336A (zh) 2017-10-05 2019-07-16 日商第一三共股份有限公司 細胞毒性ｔ細胞耗竭用組成物
JP7419248B2 (ja) 2017-12-11 2024-01-22 アバローニー バイオ，インコーポレーテッド ペリプラズム空間中におけるタンパク質の酵母ディスプレイ
CA3093205A1 (en) 2018-03-05 2019-09-12 Saitama Medical University Pharmaceutical composition for treating or preventing heterotopic ossification
KR20210018192A (ko) 2018-05-31 2021-02-17 다이이찌 산쿄 가부시키가이샤 항인간 tlr7 항체
CA3104390A1 (en) 2018-06-22 2019-12-26 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
KR20210030267A (ko) 2018-07-10 2021-03-17 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
EP3831853A4 (de) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited Protein-erkennende arzneimitteleinheit eines antikörper-wirkstoff-konjugats
JPWO2021020282A1 (de) 2019-07-26 2021-02-04
EP4049675A4 (de) 2019-10-25 2023-11-22 Daiichi Sankyo Company, Limited Kombination von anti-garp-antikörper und immunregulator
CA3166364A1 (en) 2019-12-31 2021-07-08 Antagonis Compositions and methods for the prevention of s. aureus infection
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
CN116194475A (zh) 2020-08-31 2023-05-30 Sab有限责任公司 对冠状病毒蛋白具有特异性的有蹄类动物源性多克隆免疫球蛋白和其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155114A (en) * 1874-09-15 Improvement in methods of laying and forming cast-iron pipes
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
EP0530216A4 (en) 1990-04-19 1993-06-30 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
JP4128227B2 (ja) * 1997-03-14 2008-07-30 バイオジェン・アイデック・インコーポレイテッド 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター
US6368821B1 (en) 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
US6632672B2 (en) * 1998-08-19 2003-10-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US20020155114A1 (en) 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1194540A1 (de) 1999-07-14 2002-04-10 Clontech Laboratories Inc. Rekombinase-basierende methoden zur herstellung von expressionsvektoren und zusammensetzungen für ihre verwendung
AU6364800A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system
KR100831118B1 (ko) * 2000-05-26 2008-05-20 심포젠 에이/에스 알레르기를 치료하기 위한 재조합 폴리클로날 항체 또는정제된 폴리클로날 항체
EP1293564A4 (de) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp Expressionsvektor zum screenen von zellen mit hoher expression von rekombinanten proteinen, transformand mit hoher expression eines rekombinanten proteins und dessen verwendung
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
EP1337631A2 (de) * 2000-11-28 2003-08-27 Applied Molecular Evolution, Inc. Eukaryontische expressionsgenbanken basierend auf der doppel lox rekombiantion und methoden zu deren verwendung
US20030044398A1 (en) 2001-03-20 2003-03-06 Robl James M. Methods for producing antibodies in mammals
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
WO2004029284A2 (en) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20060275766A1 (en) 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1711529A1 (de) 2004-01-21 2006-10-18 Novozymes A/S Herstellung eines monoklonalen antikörpers in einem heterokaryotischen pilz oder einer pilzwirtszelle
ATE548657T1 (de) 2004-07-20 2012-03-15 Symphogen As Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie
EP1771483A1 (de) 2004-07-20 2007-04-11 Symphogen A/S Rekombinanter polyklonaler anti-rhesus-d-antikörper und herstellungsverfahren
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
KR20080113223A (ko) 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
TW200846362A (en) 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante

Also Published As

Publication number Publication date
AU2004203727A1 (en) 2004-07-22
EP1583830A2 (de) 2005-10-12
NZ541458A (en) 2006-04-28
AU2004203727C1 (en) 2008-08-21
KR101024443B1 (ko) 2011-03-23
KR20050101538A (ko) 2005-10-24
CA2512647A1 (en) 2004-07-22
US20090136498A1 (en) 2009-05-28
IL169101A (en) 2009-02-11
EP1762617A1 (de) 2007-03-14
HK1078896A1 (en) 2006-03-24
WO2004061104A2 (en) 2004-07-22
AU2004203727B2 (en) 2008-01-31
ES2273202T3 (es) 2007-05-01
DK1583830T3 (da) 2007-01-15
EA013225B1 (ru) 2010-04-30
JP2006515520A (ja) 2006-06-01
BRPI0406678A (pt) 2005-12-20
CA2512647C (en) 2013-10-08
EA200501101A1 (ru) 2006-02-24
PT1583830E (pt) 2006-11-30
EP1583830B1 (de) 2006-09-06
ATE338816T1 (de) 2006-09-15
MXPA05006724A (es) 2005-09-08
SI1583830T1 (sl) 2006-12-31
JP4589914B2 (ja) 2010-12-01
US9163232B2 (en) 2015-10-20
JP2010268806A (ja) 2010-12-02
DE602004002275T2 (de) 2007-09-06
WO2004061104A3 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
DE602004002275D1 (de) Verfahren zur herstellung rekombinanterpolyklonaler proteine
EA200700249A1 (ru) Рекомбинантное поликлональное антитело против резус-фактора d и способы его получения
CN104854133B (zh) 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
DE602008002593D1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
CN104011080B (zh) 用于真核细胞的全长抗体展示系统及其用途
CN104024423B (zh) 用于降低抗体异质性的方法和产生其抗体的方法
CN105602960A (zh) 抗体的快速人源化
AU2016200316A1 (en) Generation of binding molecules
DE60039596D1 (de) Verfahren zur herstellung von monoklonalen antikörpern
DE69434578D1 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
CN109810188A (zh) 用于克隆和表达关联抗体可变区基因区段的快速方法
CN109906030A (zh) 用于产生仅重链抗体的经基因修饰的非人动物和方法
US10329594B1 (en) Cell lines for high level production of protein-based pharmaceuticals
CN110494163A (zh) 凝血因子viii模拟蛋白及其用途
ATE337395T1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
CN106478773A (zh) 一种人工合成的新型信号肽
ES2700442T3 (es) Método para producir anticuerpos
AU2019450349B2 (en) Cell lines for high level production of protein-based pharmaceuticals
US20210009670A1 (en) Nucleic acid molecules and applications thereof in human antibody
CN104558180B (zh) 靶向t淋巴细胞的人源单链抗体
CN106478774A (zh) 一种用于蛋白质表达的信号肽
CN118339304A (zh) 克隆的中国仓鼠卵巢细胞及其用途
CN110483641A (zh) 干扰素诱导型gtp酶的单克隆抗体及其应用
Goldsby Biotechnology: A selective survey
WO1996029410A1 (en) In vivo generation of antibodies against antigens secreted in a host by transfected mel cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition